Cassava Sciences | PTIE - Gross Profit On Sales

Stock Price
2.03
Daily Change
0.14 7.41%
Monthly
-6.88%
Yearly
-10.57%
Q1 Forecast
1.93

Cassava Sciences reported $-3.96M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Abbott USD 6.54B 625M Dec/2025
Amgen USD 6.48B 307M Sep/2025
Biogen USD 1.65B 34.6M Dec/2025
Cassava Sciences USD -3.96M 1.16M Sep/2025
Eisai JPY 151.84B 8.21B Sep/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Geron USD 46.18M 1.66M Sep/2025
J&J USD 16.6B 118M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.82B 695M Sep/2025
Pfizer USD 3.54B 7.61B Sep/2025
Roche Holding CHF 22.09B 10.04B Dec/2025